These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34919964)

  • 1. Oncogenic Gq/11 signaling acutely drives and chronically sustains metabolic reprogramming in uveal melanoma.
    Onken MD; Noda SE; Kaltenbronn KM; Frankfater C; Makepeace CM; Fettig N; Piggott KD; Custer PL; Ippolito JE; Blumer KJ
    J Biol Chem; 2022 Jan; 298(1):101495. PubMed ID: 34919964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
    Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
    J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Kinase Signaling Networks Driven by Oncogenic Gq/11 in Uveal Melanoma Identified by Phosphoproteomic and Bioinformatic Analyses.
    Onken MD; Erdmann-Gilmore P; Zhang Q; Thapa K; King E; Kaltenbronn KM; Noda SE; Makepeace CM; Goldfarb D; Babur Ö; Townsend RR; Blumer KJ
    Mol Cell Proteomics; 2023 Nov; 22(11):100649. PubMed ID: 37730182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Oncogenic Gα
    Lapadula D; Farias E; Randolph CE; Purwin TJ; McGrath D; Charpentier TH; Zhang L; Wu S; Terai M; Sato T; Tall GG; Zhou N; Wedegaertner PB; Aplin AE; Aguirre-Ghiso J; Benovic JL
    Mol Cancer Res; 2019 Apr; 17(4):963-973. PubMed ID: 30567972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches].
    Zhilnikova MV; Troitskaya OS; Novak DD; Atamanov VV; Koval OA
    Mol Biol (Mosk); 2024; 58(2):189-203. PubMed ID: 39355878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma.
    Visser M; Papillon JPN; Luzzio M; LaMarche MJ; Fan J; Michael W; Wang D; Zhang A; Straub C; Mathieu S; Kato M; Palermo M; Chen C; Ramsey T; Joud C; Barrett R; Vattay A; Guo R; Bric A; Chung F; Liang G; Romanowski MJ; Lam J; Thohan S; Atassi F; Wylie A; Cooke VG
    J Med Chem; 2024 Jan; 67(2):1447-1459. PubMed ID: 38198520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct targeting of Gα
    Annala S; Feng X; Shridhar N; Eryilmaz F; Patt J; Yang J; Pfeil EM; Cervantes-Villagrana RD; Inoue A; Häberlein F; Slodczyk T; Reher R; Kehraus S; Monteleone S; Schrage R; Heycke N; Rick U; Engel S; Pfeifer A; Kolb P; König G; Bünemann M; Tüting T; Vázquez-Prado J; Gutkind JS; Gaffal E; Kostenis E
    Sci Signal; 2019 Mar; 12(573):. PubMed ID: 30890659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.
    Yu FX; Luo J; Mo JS; Liu G; Kim YC; Meng Z; Zhao L; Peyman G; Ouyang H; Jiang W; Zhao J; Chen X; Zhang L; Wang CY; Bastian BC; Zhang K; Guan KL
    Cancer Cell; 2014 Jun; 25(6):822-30. PubMed ID: 24882516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uveal melanoma cells use ameboid and mesenchymal mechanisms of cell motility crossing the endothelium.
    Onken MD; Blumer KJ; Cooper JA
    Mol Biol Cell; 2021 Mar; 32(5):413-421. PubMed ID: 33405963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
    Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
    Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
    Gaffal E
    J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.
    Lapadula D; Lam B; Terai M; Sugase T; Tanaka R; Farias E; Kadamb R; Lopez-Anton M; Heine CC; Modasia B; Aguirre-Ghiso JA; Aplin AE; Sato T; Benovic JL
    Mol Cancer Ther; 2023 Jan; 22(1):63-74. PubMed ID: 36223548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
    Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
    Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of uveal melanoma oncogenes.
    Ma J; Weng L; Bastian BC; Chen X
    Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.
    Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS
    J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
    Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
    Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of quinazoline derivatives as Gαq/11 proteins inhibitors against uveal melanoma.
    Fan G; Liu L; Ye J; Xiao W; Xiong XF
    Bioorg Chem; 2024 Feb; 143():107005. PubMed ID: 38043397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
    Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
    Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.